By Jenny Hope Medical Correspondent Thousands of men with advanced prostate cancer are to receive a new drug after a double U-turn by the NHS rationing body. Enzalutamide extends life by at least five months in men who have run out of treatment options - with some surviving more than 18 months. It was initially recommended by the National Institute for Health and Care Excellence for NHS funding without curbs last October. Thousands of men with advanced prostate cancer are to receive a new drug after a double U-turn by the NHS rationing body NICE But then Nice issued revised draft guidance in January proposing restrictions affecting the vast majority of men with prostate cancer that has spread.
@highlight
Men with advanced prostate cancer to receive drug after NHS body's U-turn
@highlight
Enzalutamide extends life by at least five months in men at end of treatment options
@highlight
U-turn by NICE came after 13,500 people signed Prostate Cancer UK petition
@placeholder has now performed another U-turn in final draft guidance (to subs must retain), which seems to go back to its original position of recommending enzalutamide regardless of a patient’s previous treatment.